Latest news for Biolife Sciences (OTC:BLFE) Stock

Biolife Sciences Inc is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. The company's technologies include antimicrobial copper air filters and copper-infused textiles. Its revenues are primarily generated from the sale of sanitation products.

Biotech

News

Penny Stocks

Rumors

Commodities

Small Cap

Markets

General

BLFE

HENDERSON, NV, Aug 10, 2022 – BioLife Sciences Inc. (BioLife), a commercialization accelerator, licensor and developer of technologies, has reportedly provided investors with a significant company update throughout the course of a two-year transformation.

Is BioLife Sciences (OTCPK: BLFE) An OTC Company Primed For Growth?

Cannabis

Press Releases

BioLife Sciences (OTCPK: BLFE), a firm dedicated to developing, licensing, and distributing antimicrobial products and disruptive technologies, announced on Tuesday that it is expanding its recently announced orthomolecular medicine and natural health products department to now include a subsector dedicated to non-psychoactive cannabinoids derived from industrial hemp, includin

BioLife Sciences Inc. To Incorporate New Sub-Sector Dedicated To CBD

BIOLIFE SCIENCES INC by BIOLIFE SCIENCES INC.

Biolife Sciences Inc

Morgan Stanley analyst Dara Mohsenian maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Equal-Weight and lowers the price target from $185 to $168.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on PepsiCo, Lowers Price Target to $168

Rosenblatt analyst Barton Crockett downgrades Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) from Buy to Neutral and raises the price target from $473 to $658.

Downgrades

SPOT

Rosenblatt Downgrades Spotify Technology to Neutral, Raises Price Target to $658

Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) reported better-than-expected fiscal fourth-quarter 2024 sales <a href="https://www.benzinga.com/quote/spot/earnings">results on Tuesday</a>. 
Spotify reported quarterly earnings of $1.88 per share, which missed the analyst consensus estimate of $2.06 per share. The company reported quarterly sales of $4.53 billion (4.24 billion euros), up by 16% year-on-year, which beat the analyst consensus estimate of $4.15 billion.
Spotify expects fiscal first-quarter 2025 revenue of $4.48 billion (4.2 billion euros) versus a consensus of $4.17 billion and total MAUs of 678 million. Spotify paid $10 billion to the music industry in 2024, contributing ~$60 billion since its founding. The premium subscribers rose to 252 million.
Spotify shares gained 13.2% to close at $621.77 on Tuesday.
These analysts made changes to their price targets on Spotify following earnings announcement.
<ul>
<li>Canaccord Genuity analyst Maria Ripps maintained Spotify Technology with a Buy and raised the price target from $650 to $700.</li>
<li>Guggenheim analyst Michael Morris maintained the stock with a Buy and raised the price target from $520 to $675.</li>
</ul>
Considering buying SPOT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="626" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05075446/image-2-8-1024x626.png" alt="" class="wp-image-767033" style="width:558px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05075446/image-2-8-1024x626.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05075446/image-2-8-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05075446/image-2-8-768x469.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05075446/image-2-8.png 1083w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Earnings

Trading Ideas

These Analysts Increase Their Forecasts On Spotify After Q4 Results

Morgan Stanley analyst Terence Flynn maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Equal-Weight and lowers the price target from $113 to $106.

Morgan Stanley Maintains Equal-Weight on Merck & Co, Lowers Price Target to $106

The energy transition is reshaping the global mining industry, with demand for critical minerals expected to surge over the coming decades. A shift toward renewable energy and electrification drives demand for commodities like copper, nickel, and <a target="_blank" href="https://www.benzinga.com/etfs/23/07/33233340/rare-earth-elements-explained" rel="noreferrer noopener">rare earth elements</a>.
According to BDO's Annual Mining Report, the demand for key energy transition minerals will <a target="_blank" href="https://www.bdo.co.uk/en-gb/insights/industries/natural-resources-and-energy/annual-mining-report" rel="noreferrer noopener">nearly triple by 2030</a> and quadruple by 2040.
Copper remains a cornerstone of the transition, as it is the only critical mineral vital for all clean energy technologies, such as solar, wind, electric vehicle (EV) manufacturing, and power grids.
While copper prices hit a record high in mid-2024, they later softened due to weak demand from China's property market. In 2025, forecasts suggest continued price constraints due to high inventories despite the long-term positive outlook.
Merger and acquisition activity has surged – with mining giant BHP <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/05/39068033/time-runs-out-for-bhp-deal-49-billion-acquisition-of-anglo-american-proves-too-complex-to-solve" rel="noreferrer noopener">unsuccessfully bidding</a> for Anglo American and launching a <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/40031488/bhp-to-unlock-south-american-copper-riches-partners-with-lundin-for-filo-acquisition" rel="noreferrer noopener">joint venture</a> with Lundin. Meanwhile, sector leader Freeport-McMoRan is opting for <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/41098074/freeport-mcmoran-sticks-with-organic-growth-takes-advantage-of-geodiversity" rel="noreferrer noopener">capex-driven internal expansion</a>.
Nickel, a metal essential for battery technologies, has faced a turbulent period. In 2024, an oversupply from Indonesia and China led to <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/07/39749321/bhp-halts-nickel-mine-were-not-able-to-overcome-economic-challenges-driven-by-oversupply" rel="noreferrer noopener">mine closures</a>, including those operated by Glencore and BHP. However, a rebound is expected in 2025 as supply surpluses narrow and demand for EV batteries remains strong.
Despite the forecasted price stabilization, industry players remain cautious, with some automakers shifting towards alternative battery chemistries that reduce dependence on nickel.
Zinc, another key transition metal used in wind and solar infrastructure, experienced a sluggish first half of 2024 due to subdued industrial activity but rebounded later in the year thanks to Chinese stimulus measures.
In 2025, BDO expects the demand to strengthen as renewable energy projects ramp up. Still, supply constraints and logistical challenges may continue to drive price fluctuations.
The rare earth element market is also in focus as countries look to diversify their supply chains since the U.S., China, and Myanmar account for 92% of global production.
President Donald Trump's recent remark shows the importance of this group of metals, which is vital for producing magnets.
"We're looking to do a deal with Ukraine where they're going to secure what we're giving them with their rare earths and other things," he said,<a target="_blank" href="https://www.reuters.com/markets/commodities/trump-says-he-wants-ukraine-supply-us-with-rare-earths-2025-02-03/" rel="noreferrer noopener"> per</a> Reuters.
Looking forward, despite opportunities created by the energy transition, BDO notes a pressing demographic challenge.
Per McKinsey's <a target="_blank" href="https://www.mckinsey.com/industries/metals-and-mining/our-insights/has-mining-lost-its-luster-why-talent-is-moving-elsewhere-and-how-to-bring-them-back" rel="noreferrer noopener">survey</a> of Canadian mining companies, 70% of people between 15 and 30 years old would not consider working in mining. Meanwhile, between 2016 and 2022, the number of mining engineering graduates in the U.S. fell by 41%.
While the industry tries to reverse the trend by integrating advanced technologies and enhancing sustainability efforts to create a more attractive work environment – closing the skills gap remains a key. To drive the next phase of mining evolution, the future workforce will need expertise in automation, AI, and environmental management.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43432736/copper-stocks-on-shaky-ground-jpmorgan-analysts-say-tariffs-deepseek-cloud-outlook" target="_blank" rel="noreferrer noopener">Copper Stocks On Shaky Ground, JPMorgan Analysts Say: Tariffs, DeepSeek Cloud Outlook</a></li>
</ul>
Photo via Shutterstock

Global

COPX

CPER

PICK

PowerShares Dynamic Basic Materials Sector Portfolio

Market Vectors Rare Earth/Strategic Metals Etf

REMX

SLVP

Critical Metal Demand To Triple By 2030, But Demographics Pose Risks

Rosenblatt analyst Kevin Cassidy maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and raises the price target from $22 to $30.

BTDR

Rosenblatt Maintains Buy on Bitdeer Technologies, Raises Price Target to $30

WIIM

EVAX

Evaxion Biotech shares are trading lower. The stock may be moving on continued weakness after Lake Street cut its price target on the stock yesterday from $35 to $6.

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Hartford Finl Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Outperform and raises the price target from $139 to $140.

Keefe, Bruyette & Woods Maintains Outperform on Hartford Finl Servs Gr, Raises Price Target to $140

Solidion Technology shares are trading lower on possible continued weakness after receiving a NASDAQ notice yesterday regarding its minimum market value of publicly held shares.

Guggenheim analyst Michael Morris maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $520 to $675.

Guggenheim Maintains Buy on Spotify Technology, Raises Price Target to $675

AudioCodes Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUDC#NASDAQ">AUDC</a>) reported better-than-expected<a href="https://www.benzinga.com/quote/AUDC/earnings"> fourth-quarter earnings on Tuesday</a>.
The company posted quarterly earnings of 37 cents per share which beat the analyst consensus estimate of 23 cents per share. The company reported quarterly sales of $61.554 million which beat the analyst consensus estimate of $61.510 million.
&#8220;I am pleased to report solid fourth quarter performance, with healthy growth in key business lines, taking us further on our transformative evolution to a cloud software and services company,&#8221; said Shabtai Adlersberg, President and Chief Executive Officer of AudioCodes.
AudioCodes shares gained 5.3% to close at $10.66 on Tuesday.
These analysts made changes to their price targets on AudioCodes following earnings announcement.
<ul>
<li>Needham analyst Ryan Koontz maintained AudioCodes with a Buy and raised the price target from $11 to $12.5.</li>
<li>Barclays analyst Ryan Macwilliams maintained the stock with an Underweight rating and increased the price target from $9 to $10.</li>
</ul>
Considering buying AUDC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074824/image-44-1024x486.png" alt="" class="wp-image-767025" style="width:457px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074824/image-44-1024x486.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074824/image-44-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074824/image-44-768x364.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074824/image-44.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

AUDC

AudioCodes Analysts Boost Their Forecasts Following Better-Than-Expected Earnings

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) with a Outperform and raises the price target from $110 to $115.

Keefe, Bruyette & Woods Maintains Outperform on Axis Capital Holdings, Raises Price Target to $115

FirstService (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSV#NASDAQ">FSV</a>) reported quarterly earnings of $1.34 per share which missed the analyst consensus estimate of $1.37 by 2.19 percent. This is a 20.72 percent increase over earnings of $1.11 per share from the same period last year. The company reported quarterly sales of $1.36 billion which beat the analyst consensus estimate of $1.33 billion by 2.89 percent. This is a 26.51 percent increase over sales of $1.08 billion the same period last year.

Earnings Beats

Earnings Misses

FirstService Q4 Adj  EPS $1.34 Misses $1.37 Estimate, Sales $1.36B Beat $1.33B Estimate

VLCN

Volcon shares are trading lower after the company announced a public offering of common stock and warrants.

The most oversold stocks in the financial sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">PayPal Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>)</h3>
<ul>
<li>On Feb. 4, PayPal reported fiscal fourth-quarter revenue growth of 4% year over year to $8.37 billion, topping the analyst consensus estimate of $8.26 billion. The company reported an adjusted EPS of $1.19, beating the analyst consensus estimate of $1.12. The company' stock fell around 12% over the past five days and has a<a href="https://www.benzinga.com/quote/PYPL"> 52-week low of $55.77</a>.</li>
<li>RSI Value: 21.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>PYPL Price Action: Shares of PayPal fell 13.2% to close at $77.72 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest PYPL <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05044712/image-35.png" alt="" class="wp-image-766680" style="width:665px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05044712/image-35.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05044712/image-35-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05044712/image-35-768x708.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>On Feb. 4, UBS Group reported fourth-quarter 2024 sales of $11.6 billion. That's up 7% year-over-year, beating the consensus of $11.2 billion. Underlying revenues upped 6% year-over-year to $11 billion, led by the performance of core businesses. The company's stock fell around 9% over the past five days and<a href="https://www.benzinga.com/quote/UBS"> has a 52-week low</a> of $26.00.</li>
<li>RSI Value: 29.4</li>
<li>UBS Price Action: Shares of UBS fell 7.2% to close at $32.41 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1">UBS stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045048/image-36.png" alt="" class="wp-image-766685" style="width:654px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045048/image-36.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045048/image-36-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045048/image-36-768x698.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Virtus Investment Partners Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>)</h3>
<ul>
<li>On Jan. 31, Virtus Investment Partners posted upbeat quarterly results. The company's stock fell around 10% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/VRTS">low of $190.42</a>.</li>
<li>RSI Value: 25.3</li>
<li>VRTS Price Action: Shares of Virtus Investment Partners fell 1% to close at $194.56 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1">breakout in VRTS shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="875" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045458/image-37.png" alt="" class="wp-image-766696" style="width:557px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045458/image-37.png 875w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045458/image-37-300x285.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045458/image-37-768x730.png 768w" sizes="(max-width: 875px) 100vw, 875px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Long Ideas

Pre-Market Outlook

PYPL

VRTS

Top 3 Financial Stocks That May Rocket Higher This Quarter

RSVR

Reservoir Media shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY25 revenue guidance above estimates.

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Outperform and lowers the price target from $196 to $194.

Keefe, Bruyette & Woods Maintains Outperform on Apollo Global Management, Lowers Price Target to $194

Barclays analyst Tom O'Malley maintains Cirrus Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) with a Equal-Weight and raises the price target from $105 to $115.

CRUS

Barclays Maintains Equal-Weight on Cirrus Logic, Raises Price Target to $115

Keybanc analyst Eric Gonzalez maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Overweight and lowers the price target from $66 to $64.

Keybanc Maintains Overweight on Chipotle Mexican Grill, Lowers Price Target to $64

The digital asset community is approaching the newfound embrace of crypto by the Trump administration with cautious optimism, after a Tuesday press conference led by David Sacks, <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43477333/crypto-czar-sacks-says-potential-bitcoin-reserve-to-be-one-of-crypto-committees-first-priorities">the designated &#8220;Crypto Czar.&#8221;</a>
What Happened: While the rhetoric surrounding innovation and regulatory clarity has been well-received, industry experts are now scrutinizing the actual plans and questioning whether the proposed changes will truly benefit the broader crypto ecosystem.
Experts see this as a critical juncture, but they also caution against potential pitfalls.
The formation of a bipartisan working group was a central announcement, signaling an effort to harmonize regulatory efforts across Congress and the executive branch. 
The initiative aims to create a framework for stablecoins and market structure legislation, which could have profound implications for the global financial system.
Speaking with Benzinga, Todd Ruoff, CEO of Autonomys, pointed out the measured approach outlined by Sacks. 
"Lawmakers are ‘exploring the possibilities,'" Ruoff said, noting that the emphasis was on forming committees, educating Congress, and determining the feasibility of frameworks. 
While these early steps are crucial, Ruoff highlighted the economic implications of stablecoin legislation. 
"Higher demand for T-bills would cause their prices to go up, which in turn pushes yields down and lowers interest rates," he said. 
This approach could tie stablecoin adoption directly to the strength of the U.S. dollar and the Treasury market.
Notably, stablecoins could serve as both a technological and economic tool. 
By linking their reserve requirements to U.S. Treasuries, stablecoins could provide a new channel for Treasury demand, reinforcing the dollar's dominance. 
However, this integration would require careful calibration to avoid market distortions, especially given the size of the stablecoin market, which currently exceeds $227 billion.
Paul Neuner, founder of Telcoin, told Benzinga the announcement marks a turning point for crypto in the U.S., where regulators are no longer trying to suppress innovation but are instead working to position the country at the center of digital assets.
He drew parallels to the regulatory evolution seen during the rise of Web 2.0, emphasizing that crypto regulation should focus on gateways like digital asset banks rather than attempting to control decentralized networks.
The media briefing also highlights a shift in regulatory thinking. 
Instead of enforcing broad restrictions, the focus on key entry points like digital asset banks suggests a pragmatic approach. 
This strategy could ensure compliance without stifling innovation, fostering an environment where blockchain-based financial services can thrive alongside traditional systems.
Joao Reginatto, Chief Strategy Officer at M^0, praised the administration's progress on stablecoin clarity. 
"The pace with which the Trump administration is moving through the phases is welcomed by the sector," Reginatto told Benzinga. 
He highlighted the balance between federal oversight and flexibility for state regulators, calling it a "reasonable approach."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43475386/exclusive-anthony-scaramucci-warns-donald-trumps-crypto-promises-may-be-a-mirage">EXCLUSIVE: Anthony Scaramucci Warns Donald Trump&#8217;s Crypto Promises May Be A &#8216;Mirage&#8217;</a>
Why It Matters: Experts point to a potential decentralization of stablecoin oversight, with state regulators playing a significant role.
This could align with the broader U.S. tradition of federalism while addressing the specific needs of different jurisdictions. 
However, it also raises questions about uniformity and consistency, particularly for large-scale issuers operating across states.
Speaking with Benzinga, Laurenth Alba, Head of Business Development at Rome Protocol, sees the bipartisan effort as a clear sign of crypto's growing importance and said the bipartisan working group and Senate stablecoin bill suggest that crypto is now a national economic and geopolitical priority, not just a speculative asset class.
However, he warned that overregulation could drive users toward decentralized alternatives. "The real threat to dollar hegemony isn't crypto—it's bad policy that pushes financial innovation beyond U.S. control."
There is a delicate balance regulators must strike. 
While integrating stablecoins into the financial system could bolster the dollar's dominance, excessive control risks alienating innovators and users. 
This could create an unintended shift toward decentralized stablecoins or alternative financial systems, eroding the very dominance the U.S. seeks to strengthen.
Alice Liu, Research Lead at CoinMarketCap, acknowledged the administration's recognition of past regulatory missteps. 
"David Sacks and team acknowledged past policies have been inconsistent and, at times, arbitrary—pushing crypto innovation offshore," Liu told Benzinga. 
She emphasized that the focus on stablecoins is a logical first step, given their role in global financial markets. 
However, Liu noted a missed opportunity in the absence of a clearer plan for Bitcoin reserves, which some stakeholders had anticipated.
While stablecoin regulation is critical, Bitcoin remains central to the crypto ecosystem. 
A well-defined policy on Bitcoin could provide additional clarity, particularly as other nations explore BTC as a reserve asset.
Dave Sedacca, Head of Finance at Parity Technologies, viewed the announcement as a positive step but noted market expectations for more impactful measures. 
"The emphasis on reinforcing the dollar from a digital perspective was encouraging, and it will be intriguing to see how the BRICS nations respond," Sedacca said.
As BRICS nations explore alternatives to the dollar, the U.S.'s focus on digital assets could serve as a counterbalance. 
However, this will require swift and effective action to avoid falling <a href="https://www.benzinga.com/markets/cryptocurrency/23/07/33333534/brics-emerges-as-new-global-powerhouse-us-dollar-faces-uncertain-future">behind in the global financial race.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43473182/could-the-trump-established-sovereign-wealth-fund-invest-in-bitcoin-nvidia-tiktok">Could The Trump-Established Sovereign Wealth Fund Invest In Bitcoin, Nvidia, TikTok?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

EXCLUSIVE: 'Crypto Czar' Charm Offensive Welcomed, But Experts Wonder: Will US Policy Deliver?

Biolife Sciences

HENDERSON, NV, Aug 10, 2022 &ndash; BioLife Sciences Inc. (BioLife), a commercialization accelerator, licensor and developer of technologies, has reportedly provided investors with a significant company update throughout the course of a two-year transformation.

Over the course of the last two years, BioLife has gone through a number of changes evolving into a revamped corporate entity focused on disrupting various consumer verticals, with a specific focus on health and wellness.

Let&rsquo;s take a look at some of what the company has been up to over the last two years.

BioLife Sciences is Born:

In June of 2020, the OTC Markets public entity formerly known as Rhino Novi Inc. (RNOV) underwent a reverse merger transaction &ndash; changing its name and ticker symbol to BioLife Sciences Inc. (BLFE). While Rhino Novi originally focused on VOIP products, the newly formed BioLife would focus on developing and marketing disruptive technologies to a variety of consumer verticals.

Harnessing the Antimicrobial Power of Copper?

BioLife has reported it focused on the utilization of the natural antimicrobial power of copper and harnessing its innate benefits into everyday textiles.&nbsp;

This dynamic elemental metal has a wide variety of beneficial traits, including being required by all plants and animals as a key mineral and nutrient necessary for survival.&nbsp;

In the case of humans specifically, copper reportedly helps to boost red blood cell production, provides support to the immune system, and helps to keep nerve cells healthy.

For plants, copper is a fundamental micronutrient that is a critical element of plant enzymes, it is essential for plants&rsquo; respiration, plays a key role in plant cell wall strength and contributes to the overall strength of the plant.

More recently, copper has been shown to provide antimicrobial efficacy associated with copper alloy touch surfaces. Some hospital studies have shown copper&rsquo;s effectiveness in lowering E.coli counts on brass doorknobs, as well as SARS-CoV-2, Rhinovirus Type 37, Rotavirus Strain WA, and Human Coronavirus 229E.

BioLife says it has focused its attention on incorporating the power of copper into everyday products which are fabric-based and disruptive, in contrast to the market&rsquo;s current offering. Some of these products in development include copper-infused fabric gardening pots, copper-infused gardening gloves, copper-infused microfiber towels and copper-infused air filters.

What is MFusion?&nbsp;

The company states that traditional copper-infused products that consumers will find on the market today provide limited-to-partial copper coverage. This means that there could are often gaps in the copper coverage, resulting in less-than-optimal results.&nbsp;

BioLife addresses this problem with the introduction of their unique copper infusion process: MFusion. MFusion infuses copper into every sub-bundle of the fabric, providing more complete coverage.

When copper is infused into textiles via MFusion, the resulting fabrics benefit from 100% evenly distributed copper coverage. MFusion can be applied to any textile &ndash; from t-shirts to air filters &ndash; with the result being total copper infusion.

The 2022 Acquisition of Health Box LLC &ndash; What&rsquo;s Next?

In February of 2022, BioLife completed the acquisition of Health Box LLC &ndash; an Arizona-based orthomolecular medicine and natural health products company.&nbsp;

By completing this acquisition - and appointing Nika Jaksic, Health Box&rsquo;s founder, as the new COO, the company believes it has positioned itself to enter the orthomolecular and natural health products space.

In order to facilitate the Company&rsquo;s aggressive expansion plans, the Company filed for a Regulation A+ Tier 1 Offering. The SEC qualified BioLife and the Company is eligible to raise up to $20 million.

If successful in its capital raise, BioLife states that they intend to pursue rapid expansion of its existing and contemplated product offerings, audits, and the potential of filling towards uplisting to the OTC Venture Market (OTCQB).&nbsp;

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Featured photo by Ra Dragon on &nbsp;<a href="https://unsplash.com/photos/Uwq_F5G4yOo">Unsplash</a>

BioLife Sciences (OTCPK: BLFE), a firm dedicated to developing, licensing, and distributing antimicrobial products and disruptive technologies, announced on Tuesday that it is expanding its recently announced orthomolecular medicine and natural health products department to now include a subsector dedicated to non-psychoactive cannabinoids derived from industrial hemp, including, but not limited to, cannabidiol (CBD) products.

This new subsector will focus on clinical hemp natural health products in addition to non-psychoactive cannabinoid research and development.

BioLife aims to focus on products highlighting hemp&#39;s naturally occurring cannabinoids (excluding any psychoactive cannabinoids such as THC), with a focus on CBD, CBG and CBN. The company&#39;s focus will be founded in medical products, beverages, creams, salves, efficacious supplements, superfood concentrates, nutraceutical formulations, and advanced orthomolecular and natural health products.

This latest announcement by BioLife is directly founded on the Company&#39;s recent acquisition of Health Box LLC, which facilitated the expansion of the Company&#39;s scope to micronutrients, medicinal herbal supplements, botanicals and holistic merchandise.

&ldquo;The Brightfield Group recently announced projections for the hemp CBD industry to continue to expand in 2022, with a projection of nearly 400% growth to $22 billion by the end of the year,&rdquo; the company noted in a press release. &ldquo;CBD usage has steadily increased in the U.S. since 2018, with multiple peer-reviewed studies having confirmed that the cannabinoid may help with a wide variety of ailments and conditions, including, but not limited to, pain, stress, weight loss, anxiety and depression.&quot;

Nika Jaksic, COO of BioLife Sciences added that with CBD sales on the rise, they expect e-commerce sales to also gain.

&quot;We believe CBD sales will continue their strong upward trend with current e-commerce sales soon being joined by consumers returning to brick and mortar options, as the pandemic wanes and disposable incomes continue to rise. CBD and other cannabinoids found in the hemp plant are very helpful supplements, as evidenced by continuous studies highlighting that we haven&#39;t even begun to understand all of these healing cannabinoid&#39;s abilities and uses,&quot;&nbsp;Jaksic&nbsp;said&nbsp;.

Image By Ilona Szentivanyi.&nbsp;

Comments

Biolife Sciences

News

Latest news for Biolife Sciences (OTC:BLFE) Stock

Monday, August 15, 2022

Wednesday, March 02, 2022

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga